AUGMENT-101 Updated Results and Longer Follow-Up of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia

Panelists discuss how the updated results and longer follow-up from the AUGMENT-101 study of revumenib demonstrate its potential to improve outcomes in patients with relapsed/refractory KMT2Ar acute leukemia, offering a promising new option in this challenging subset of acute myeloid leukemia.

EP: 1.All Oral Regimen of Oral Azacitidine and Venetoclax for Newly Diagnosed and Relapsed/Refractory AML

Now Viewing

EP: 2.AUGMENT-101 Updated Results and Longer Follow-Up of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia

Recent Videos